Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Viracta Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Viracta Therapeutics announced earnings per share of $-0.47 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.31 on revenue of $0.00.
Viracta Therapeutics 's are down 53.92% and is trading at $3.32 , still down 45.53% from its 52 week high of $6.09 set on Tuesday, November 16, 2021.
Viracta Therapeutics follows other major Healthcare sector earnings this month
Viracta Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar